Yusheng R. Wang
Taiyuan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial.
Journal: Nature communications
Published: August 28, 2025
Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.
Journal: British journal of cancer
Published: April 15, 2025
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 07, 2025
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: March 27, 2025
RC48 Induces Senescence in HER2-Expressing Colon Cancer Cells by Activating the CDKN1A-RB-E2F1 Pathway.
Journal: Current cancer drug targets
Published: February 24, 2025
Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study.
Journal: Anti-cancer drugs
Published: February 04, 2025
Efficacy observation of sequential TAS-102 following regorafenib as a later-line treatment in patients with metastatic colorectal cancer: a cohort study.
Journal: Journal of gastrointestinal oncology
Published: January 15, 2025
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies.
Journal: Cancer immunology, immunotherapy : CII
Published: December 02, 2024
A comparison between single and fractionated doses of albumin-bound paclitaxel in the treatment of advanced esophageal cancer: A multicenter case-control study.
Journal: Science progress
Published: November 19, 2024
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Journal: Nature medicine
Published: September 29, 2024
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.
Journal: Clinical and translational science
Published: April 21, 2024
Envafolimab Inhibits the Growth of Gastric Cancer Cells with Low PD-L1 Expression through the DDX20/NF-κB/TNF-α Signaling Pathway.
Journal: Current cancer drug targets
Published: March 27, 2024
Last Updated: 09/26/2026